Dr. Garmezy is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
Sarah Cannon Research Institute at TN Oncology
Nashville, TN 37203- Is this information wrong?
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2018 - 2021
University of Michigan Health SystemResidency, Internal Medicine, 2015 - 2018
Baylor College of MedicineClass of 2015
Certifications & Licensure
TN State Medical License 2021 - 2025
TX State Medical License 2018 - 2022
MI State Medical License 2015 - 2018- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors.Harding, J., Cesar A Perez, Li-Tzong Chen, Do-Youn Oh, Paul Severson, Betty Y Tam, Benjamin Garmezy, Mitesh J Borad, Shumei Kato, James J Harding, Rastilav Bahleda, Ch...> ;Cancer Research Communications. 2024 Apr 30
- 28 citationsClinical and Molecular Characterization ofMutations as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Cancers.Garmezy, B., Gheeya, J., Lin, H., Huang, Y., Kim, T., Jiang, X., Thein, K., Pilié, P., Zeineddine, F., Wang, W., Shaw, K., Rodon, J., Shen, J., Yuan, Y., Meric-Bernsta...> ;JCO Precision Oncology. 2022 Feb 1
- 13 citationsAll bone metastases are not created equal: Revisiting treatment resistance in renal cell carcinoma.Ava Brozovich, Benjamin Garmezy, Tianhong Pan, Liyun Wang, Mary C. Farach-Carson, Robert L. Satcher> ;Journal of Bone Oncology. 2021 Oct 20
- Join now to see all
Press Mentions
Kinnate Biopharma Inc. Receives Fast Track Designation from the U.S. Food and Drug Administration for KIN-3248, an Investigational Pan-FGFR InhibitorFebruary 14th, 2023- Kinnate Biopharma Inc. To Present Trials in Progress Poster for Its Pan-FGFR Inhibitor, KIN-3248, at the 2023 ASCO Gastrointestinal Cancers Symposium and ASCO Genitourinary Cancers SymposiumJanuary 17th, 2023
Hospital Affiliations
TriStar Centennial Medical CenterNashville, Tennessee
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
